Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors

ACS Medicinal Chemistry Letters

Volumn 6, Issue 7, 2015, Pages 798-803

  Murray, Christopher W ^a   Berdini, Valerio ^a   Buck, Ildiko M ^a   Carr, Maria E ^a   Cleasby, Anne ^a   Coyle, Joseph E ^a   Curry, Jayne E ^a   Day, James E H ^a   Day, Phillip J ^a   Hearn, Keisha ^a   Iqbal, Aman ^a   Lee, Lydia Y W ^a   Martins, Vanessa ^a   Mortenson, Paul N ^a   Munck, Joanne M ^a   Page, Lee W ^a   Patel, Sahil ^a   Roomans, Susan ^a   Smith, Kirsten ^a   Tamanini, Emiliano ^a   Saxty, Gordon ^a   more..

^a ASTEX PHARMACEUTICALS   (United Kingdom)

Author keywords

back to front kinase design; discoidin domain receptor; fragment based drug design

Indexed keywords

AMIDE; ANTINEOPLASTIC AGENT; BENZOXAZOLE DERIVATIVE; BENZYL DERIVATIVE; COLLAGEN TYPE 1; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 1; DISCOIDIN DOMAIN RECEPTOR 1 INHIBITOR; DISCOIDIN DOMAIN RECEPTOR 2; DISCOIDIN DOMAIN RECEPTOR 2 INHIBITOR; DORAMAPIMOD; IMIDAZOPYRIDINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SARACATINIB; THIAZOLE DERIVATIVE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; EC50; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LIPOPHILICITY; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84936875624     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00143     Document Type: Article

References (31)

1. Shrivastava, A.; Radziejewski, C.; Campbell, E.; Kovac, L.; McGlynn, M.; Ryan, T. E.; Davis, S.; Goldfarb, M. P.; Glass, D. J.; Lemke, G.; Yancopoulos, G. D. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors Mol. Cell 1997, 1, 25-34
2. Leitinger, B. Transmembrane collagen receptors Annu. Rev. Cell Dev. Biol. 2011, 27, 265-290
3. Vogel, W. F.; Abdulhussein, R.; Ford, C. E. Sensing extracellular matrix: an update on discoidin domain receptor function Cell. Signal. 2006, 18, 1108-1116
4. Valiathan, R. R.; Marco, M.; Leitinger, B.; Kleer, C. G.; Fridman, R. Discoidin domain receptor tyrosine kinases: new players in cancer progression Cancer Metastasis Rev. 2012, 31, 295-321
5. Zhang, K.; Corsa, C. A.; Ponik, S. M.; Prior, J. L.; Piwnica-Worms, D.; Eliceiri, K. W.; Keely, P. J.; Longmore, G. D. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis Nat. Cell Biol. 2013, 15, 677-687
6. Hammerman, P. S.; Sos, M. L.; Ramos, A. H.; Xu, C.; Dutt, A.; Zhou, W.; Brace, L. E.; Woods, B. A.; Lin, W.; Zhang, J.; Deng, X.; Lim, S. M.; Heynck, S.; Peifer, M.; Simard, J. R.; Lawrence, M. S.; Onofrio, R. C.; Salvesen, H. B.; Seidel, D.; Zander, T.; Heuckmann, J. M.; Soltermann, A.; Moch, H.; Koker, M.; Leenders, F.; Gabler, F.; Querings, S.; Ansen, S.; Brambilla, E.; Brambilla, C.; Lorimier, P.; Brustugun, O. T.; Helland, A.; Petersen, I.; Clement, J. H.; Groen, H.; Timens, W.; Sietsma, H.; Stoelben, E.; Wolf, J.; Beer, D. G.; Tsao, M. S.; Hanna, M.; Hatton, C.; Eck, M. J.; Janne, P. A.; Johnson, B. E.; Winckler, W.; Greulich, H.; Bass, A. J.; Cho, J.; Rauh, D.; Gray, N. S.; Wong, K. K.; Haura, E. B.; Thomas, R. K.; Meyerson, M. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov. 2011, 1, 78-89
7. Beauchamp, E. M.; Woods, B. A.; Dulak, A. M.; Tan, L.; Xu, C.; Gray, N. S.; Bass, A. J.; Wong, K. K.; Meyerson, M.; Hammerman, P. S. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss Mol. Cancer Ther. 2014, 13, 475-482
8. Iwai, L. K.; Payne, L. S.; Luczynski, M. T.; Chang, F.; Xu, H.; Clinton, R. W.; Paul, A.; Esposito, E. A.; Gridley, S.; Leitinger, B.; Naegle, K. M.; Huang, P. H. Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants Biochem. J. 2013, 454, 501-513
9. Bai, Y.; Kim, J. Y.; Watters, J. M.; Fang, B.; Kinose, F.; Song, L.; Koomen, J. M.; Teer, J. K.; Fisher, K.; Chen, Y. A.; Rix, U.; Haura, E. B. Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations Cancer Res. 2014, 74, 7217-7228
10. Payne, L. S.; Huang, P. H. Discoidin domain receptor 2 signaling networks and therapy in lung cancer J. Thorac. Oncol. 2014, 9, 900-904
11. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-Aminothiazole as a Novel Kinase Inhibitor Template. Structure-Activity Relationship Studies toward the Discovery of N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a Potent pan-Src Kinase Inhibitor J. Med. Chem. 2006, 49, 6819-6832
12. Li, Y.; Lu, X.; Ren, X.; Ding, K. Small Molecule Discoidin Domain Receptor Kinase Inhibitors and Potential Medical Applications J. Med. Chem. 2015, 58, 3287-3301
13. Gao, M.; Duan, L.; Luo, J.; Zhang, L.; Lu, X.; Zhang, Y.; Zhang, Z.; Tu, Z.; Xu, Y.; Ren, X.; Ding, K. Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors J. Med. Chem. 2013, 56, 3281-3295
14. Kim, H. G.; Tan, L.; Weisberg, E. L.; Liu, F.; Canning, P.; Choi, H. G.; Ezell, S. A.; Wu, H.; Zhao, Z.; Wang, J.; Mandinova, A.; Griffin, J. D.; Bullock, A. N.; Liu, Q.; Lee, S. W.; Gray, N. S. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor ACS Chem. Biol. 2013, 8, 2145-2150
15. Richters, A.; Nguyen, H. D.; Phan, T.; Simard, J. R.; Grutter, C.; Engel, J.; Rauh, D. Identification of type II and III DDR2 inhibitors J. Med. Chem. 2014, 57, 4252-4262
16. Canning, P.; Tan, L.; Chu, K.; Lee, S. W.; Gray, N. S.; Bullock, A. N. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors J. Mol. Biol. 2014, 426, 2457-2470
17. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A.; Jhoti, H. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation J. Med. Chem. 2005, 48, 414-426
18. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity J. Med. Chem. 2009, 52, 379-388
19. Johnson, C. N.; Berdini, V.; Beke, L.; Bonnet, P.; Brehmer, D.; Coyle, J. E.; Day, P. J.; Frederickson, M.; Freyne, E. J.; Gilissen, R. A.; Hamlett, C. C.; Howard, S.; Meerpoel, L.; McMenamin, R.; Patel, S.; Rees, D. C.; Sharff, A.; Sommen, F.; Wu, T.; Linders, J. T. Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase ACS Med. Chem. Lett. 2015, 6, 25-30
20. Saxty, G.; Woodhead, S. J.; Berdini, V.; Davies, T. G.; Verdonk, M. L.; Wyatt, P. G.; Boyle, R. G.; Barford, D.; Downham, R.; Garrett, M. D.; Carr, R. A. Identification of inhibitors of protein kinase B using fragment-based lead discovery J. Med. Chem. 2007, 50, 2293-2296
21. Squires, M.; Ward, G.; Saxty, G.; Berdini, V.; Cleasby, A.; King, P.; Angibaud, P.; Perera, T.; Fazal, L.; Ross, D.; Jones, C. G.; Madin, A.; Benning, R. K.; Vickerstaffe, E.; O'Brien, A.; Frederickson, M.; Reader, M.; Hamlett, C.; Batey, M. A.; Rich, S.; Carr, M.; Miller, D.; Feltell, R.; Thiru, A.; Bethell, S.; Devine, L. A.; Graham, B. L.; Pike, A.; Cosme, J.; Lewis, E. J.; Freyne, E.; Lyons, J.; Irving, J.; Murray, C.; Newell, D. R.; Thompson, N. T. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models Mol.Cancer Ther. 2011, 10, 1542-1552
22. Wyatt, P. G.; Woodhead, A. J.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Davis, D. J.; Devine, L. A.; Early, T. R.; Feltell, R. E.; Lewis, E. J.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Reule, M.; Saxty, G.; Seavers, L. C.; Smith, D. M.; Squires, M. S.; Trewartha, G.; Walker, M. T.; Woolford, A. J. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design J. Med. Chem. 2008, 51, 4986-4999
23. Bamborough, P.; Brown, M. J.; Christopher, J. A.; Chung, C. W.; Mellor, G. W. Selectivity of kinase inhibitor fragments J. Med. Chem. 2011, 54, 5131-5143
24. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9, 430-431
25. Baldwin, I.; Bamborough, P.; Haslam, C. G.; Hunjan, S. S.; Longstaff, T.; Mooney, C. J.; Patel, S.; Quinn, J.; Somers, D. O. Kinase array design, back to front: biaryl amides Bioorg. Med. Chem. Lett. 2008, 18, 5285-5289
26. Iwata, H.; Oki, H.; Okada, K.; Takagi, T.; Tawada, M.; Miyazaki, Y.; Imamura, S.; Hori, A.; Lawson, J. D.; Hixon, M. S.; Kimura, H.; Miki, H. A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases ACS Med. Chem. Lett. 2012, 3, 342-346
27. Regan, J.; Breitfelder, S.; Cirillo, P.; Gilmore, T.; Graham, A. G.; Hickey, E.; Klaus, B.; Madwed, J.; Moriak, M.; Moss, N.; Pargellis, C.; Pav, S.; Proto, A.; Swinamer, A.; Tong, L.; Torcellini, C. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate J. Med. Chem. 2002, 45, 2994-3008
28. Sanphanya, K.; Wattanapitayakul, S. K.; Phowichit, S.; Fokin, V. V.; Vajragupta, O. Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach Bioorg. Med. Chem. Lett. 2013, 23, 2962-2967
29. Pierce, A. C.; Rao, G.; Bemis, G. W. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease J. Med. Chem. 2004, 47, 2768-2775
30. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364
31. Potashman, M. H.; Bready, J.; Coxon, A.; DeMelfi, T. M., Jr.; DiPietro, L.; Doerr, N.; Elbaum, D.; Estrada, J.; Gallant, P.; Germain, J.; Gu, Y.; Harmange, J. C.; Kaufman, S. A.; Kendall, R.; Kim, J. L.; Kumar, G. N.; Long, A. M.; Neervannan, S.; Patel, V. F.; Polverino, A.; Rose, P.; Plas, S.; Whittington, D.; Zanon, R.; Zhao, H. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors J. Med. Chem. 2007, 50, 4351-4373